GlassScriptPhysician profile
Matthew C Sophy
NPI 1922071620
$2,144.56
in general payments reported to CMS, 2019-2025
11 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $169 · 2021: $259 · 2022: $239 · 2023: $366 · 2024: $287 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.90 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $795.16 | 2019-2024 | Mounjaro, Zepbound |
| Amgen INC. | $413.90 | 2019-2025 | Prolia, Repatha, Otezla |
| Novo Nordisk INC | $333.21 | 2019-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $316.14 | 2019 | |
| Sunovion Pharmaceuticals INC. | $96.61 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $90.87 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $47.36 | 2023-2024 | Gemtesa |
| Abbvie INC. | $14.25 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $13.05 | 2019 | |
| Glaxosmithkline, LLC. | $12.80 | 2023 | Trelegy Ellipta, Shingrix |
| Irhythm Technologies, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sophy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.